welcome to DuchenneXchange
- a positively charged Duchenne muscular dystrophy community.- join today!
- log in
Solid Biosciences Reports First Quarter 2019 Financial Results and Provides Business Update
Solid Biosciences Inc. (Nasdaq: SLDB) today reported financial results for the first quarter ended March 31, 2019 and provided a business update.
“We have continued to advance our programs for Duchenne muscular dystrophy over the last few months, particularly our lead microdystrophin gene therapy candidate, SGT-001. Building on our findings from the preliminary Phase I/II clinical data that we announced in February, we initiated dosing at 2E14 vg/kg in the second cohort of patients,” said Ilan Ganot, Chief Executive Officer, President and Co-Founder of Solid Biosciences. “Now, we are working to progress as quickly as possible, and we look forward to providing additional data later this year.”
rareRelated
-
Dr. Eric Olson CRISPR/Cas9 Presentation at CureDuchenne Careshttps://www.youtube.com/watch?v=P-Q8HFXk...
-
CRISPR-SKIP: Programmable gene splicing with single base editorsCRISPR gene editing has revolutionized b...
-
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
-
Gene Therapy as a Potential Therapeutic Option for Duchenne Muscular Dystrophy: A Qualitative Preference Study of Pa...Objectives: Duchenne muscular dystrophy...
-
New therapeutic approaches: I.9 Treatment of Duchenne muscular dystrophy: current efforts, bottlenecks and future pr...In the last decade a number of therapeut...
-
Duchenne Muscular Dystrophy Awaits Gene TherapySolid’s gene therapy disappoints in th...
-
Update in Duchenne and Becker Muscular DystrophyPurpose of Review: The purpose of this ...
